FindTrial
Sign In

EsoGuard

DEVICE4 trials

Sponsors

Lucid Diagnostics, Inc., Denver Health and Hospital Authority, Case Comprehensive Cancer Center

Conditions

Anorexia Nervosa, Binge Eating/Purging TypeBarrett EsophagusBarrett's Esophagus Without DysplasiaBarretts Esophagus With DysplasiaEating DisordersEsophageal AdenocarcinomaEsophagus AdenocarcinomaGastroesophageal Reflux

Unknown Phase

Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE
CompletedNCT04293458
Lucid Diagnostics, Inc.Barrett Esophagus, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia +1
Start: 2020-02-28End: 2022-08-22Updated: 2023-01-25
CLUE: CLinical Utility Study of EsoGuard
CompletedNCT06030180
Lucid Diagnostics, Inc.Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophagus Adenocarcinoma
Start: 2023-02-23End: 2024-12-13Updated: 2025-06-27
Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype
RecruitingNCT06532734
Denver Health and Hospital AuthorityAnorexia Nervosa, Binge Eating/Purging Type, Barrett Esophagus, Eating Disorders +3
Start: 2024-11-12End: 2026-11-30Target: 25Updated: 2025-12-10
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
RecruitingNCT06687603
Case Comprehensive Cancer CenterBarrett Esophagus, Esophageal Adenocarcinoma, Gastroesophageal Reflux
Start: 2025-03-10End: 2029-09-27Target: 800Updated: 2026-09-15

Related Papers

Use of a Two-Gene Methylated DNA Biomarker Assay and Nonendoscopic Balloon for Detection of Barrett Esophagus Among High-Risk Individuals in a Screening Population
The American Journal of Gastroenterology2024-11-266 citations